BPC-157 vs MGF
Extensively Studied vs limited
synergistic Complementary mechanisms. BPC-157 promotes angiogenesis; MGF activates satellite cells.
Molecular Data
BPC-157 MGF
Weight 1,419.53 Da ~2,888 Da
Half-life <30 minutes ~5-7 minutes
Chain 15 amino acids 24 amino acids
Type Pentadecapeptide IGF-1Ec splice variant C-terminal peptide
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
MGF
01 Satellite cell activation for muscle repair
02 Recovery support following mechanical stress
03 Localized tissue regeneration
04 Natural upregulation after exercise
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
MGF
100-300mcg per injection / Daily, immediately post-workout
Standard Protocol 100-300mcg Daily, post-workout
Progressive Titration 100mcg → 300mcg Daily, increasing weekly
Localized Recovery 200-300mcg Immediately post-workout
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
MGF
Injection site soreness
Mild fatigue
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Any history of cancer or neoplastic disease
Pregnancy or breastfeeding
Uncontrolled diabetes
Research Evidence
BPC-157 MGF
Status Extensively Studied limited
References 6 studies 2 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.